Good health and well being
Ensure healthy lives and promote well-being for all at all ages
At Hikma, our purpose is to provide high-quality pharmaceutical products in an inclusive and affordable way. By emphasizing quality and accessibility, we ensure that our products benefit people around the world and contribute to sustainable development. Through a combination of continuous R&D, new product launches and strategic partnerships, we remain dedicated to improving global health standards and offering greater well-being to our communities.
Providing Affordability, Accessibility and Quality to Egypt’s Oncology Sector
The Launch of our Hikma Specialized Unit
2016 marked the successful launch of our Hikma Specialized unit in Egypt as the country’s only local manufacturer for oncology products. The state of the art facility offers Egyptians and the wider region with high quality injectable and oral oncology products, helping us fulfil our vision of delivering affordability and accessibility to our populations in high need medical areas. The Hikma Specialized portfolio includes products that address an extensive variety of cancer types (solid tumors & hematology); including: Breast Cancer - Colorectal Cancer - Lung Cancer – Leukemia – Multiple Myeloma - Thalassemia and others. Through the facility’s rich pipeline and product portfolio, we hope to create long-term, sustainable value for patients and healthcare providers in Egypt and the MENA region as a whole.
Hikma Specialized Improves Access to Affordable Medicine by:
- Leveraging expertise and synergy from across our global network to drive Egypt’s oncology sector – improving local capabilities to meet rapidly evolving patient needs.
- Creating a robust local platform through which to introduce new generic products that are more economic for patients and less prone to interruptions in availability.
- Reducing costs for Egypt’s healthcare providers enabling them to offer more affordable treatment to end user patients.
“HAVING LOCALLY PRODUCED HIGH QUALITY AND HIGH TECH ONCOLOGY PRODUCTS AT AFFORDABLE PRICES AND CONSISTENT AVAILABILITY IN THE EGYPTIAN MARKET IS A SIGNIFICANT STEP FORWARD IN THE [NATIONAL] HEALTHCARE INDUSTRY WHICH SHOULD BE EMULATED BY OTHER PHARMA COMPANIES… THIS IS THE FIRST STEP WHICH INVARIABLY WILL LEAD TO INCREASED COMPLIANCE OF TREATMENT AND SIGNIFICANTLY REDUCE THE STRAIN ON PATIENTS AND THE HEALTHCARE SYSTEM IN EGYPT.”
Dr. Hamdy Abdel Azim – Chairman, Cairo Oncology Center
taken from Arab Finance article, “Hikma to bring advanced medicines to patients in need” May 6, 2016
Hikma Specialized Addresses Urgent Needs in Egypt and the Region:
- Between 2013 and 2050, Egypt is expected to witness a 3-Fold increase in cancer incidence.1
- By 2050, an estimated 72,000 Egyptians will suffer from Breast Cancer and an estimated 7,000 will suffer from Leukemia.2
- Breast Cancer comprises 15.4% of all cancer types in Egypt (2nd highest in the country).3
- β-thalassemia is Egypt’s most widespread genetic disorder, representing a major national health calamity. Its carrier rate isestimated to be between 9-10%, with approximately 1,000 Egyptians born with the disorder every year.4
More about Hikma Specialized:
- Our portfolio & pipeline for breast cancer treatment is diversified, including treatments such as: chemotherapy, hormonaltherapy & targeted therapy.
Leukemia & Hematology
- Our portfolio offers key therapeutic products for a range of Leukemia types such as chronic myeloid leukemia (CML). Hikma Specialized products target affordability and quality for patients, enabling them to experience improved quality of life during their treatment.
- Our Hikma Specialized portfolio includes high quality, affordable products for patients suffering from β-thalassemia, Egypt’s most common genetic disorder.
1 Amal S. Ibrahim, Hussein M. Khaled, Nabiel NH Mikhail, Hoda Baraka, and Hossam Kamel, “Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program,” Journal of Cancer Epidemiology, vol. 2014, Article ID 437971, 18 pages, 2014. doi:10.1155/2014/437971
4 Hussein G, Fawzy M, Sersfi TE, et al. Rapid detection of beta thalassaemia alleles in Egypt using natural or amplified created restriction sites and direct sequencing: a step in disease control. Hemoglobin. 2007;31(1):49–62. doi: 10.1080/03630260601057088. and Jiffri EH, Bogari N, Zidan KH, Teama S, Elhawary NA. Molecular updating of
β-thalassemia mutations in the Upper Egyptian population. Hemoglobin. 2010;34:538–547. doi: 10.3109/03630269.2010.526440.
Developing Capabilities to Address Chronic Disease in Jordan
Our Collaboration with the Royal Health Awareness Society
Non-communicable (NCDs) represent a significant burden on public health, particularly in developing countries such as Jordan. In 2014, Hikma collaborated with its long-standing partners, the Royal Health Awareness Society (RHAS) – a Jordanian non-profit committed to improving health and well-being – and the Ministry of Health (MoH) to support the establishment of Healthy Community Clinics (HCCs) around the country. Through comprehensive assistance efforts that included financial donations, capacity-building and training, and infrastructure investments, Hikma helped establish HCCs in Sahab and Wadi Al Seer – two low-income areas facing severe health deficits. We are dedicated to promoting sustainable improvements to health diseases standards in Jordan. Our cooperation with RHAS supported more than 550 direct beneficiaries and 2750 indirect beneficiaries within the HCCs.
HCCs and the Sustainable Development Goals
HCCs are pioneering community-based programmes established in 2011 by RHAS and the Ministry of Health. Their aim is to improve preventative services at the primary care level to empower patients and the general population at risk of NCDs. HCCs provide medical practitioners with the training and resources necessary to implement management and prevention-based care to patients in underserved communities.
HCC programmes are directly aligned with SDG target 3.4 related to the reduction of NCD mortality rates through improvements to prevention and treatment. Awareness sessions held through HCCs emphasize the risks of NCDs as well as ways to manage particular NCDs to lead a normal lifestyle. RHAS trains MoH staff (specifically nurses) on the awareness material and interactive methods of conducting sessions to at risk patients and patients learning to manage their disease. Awareness materials developed by RHAS are available at HCCs for beneficiaries to take home and spread the information. Awareness sessions help reduce premature mortality from NCDs and ease the financial burden of treatment for the Jordanian healthcare system. Some of the major issues tackled during the sessions include cardiovascular diseases, cancer, diabetes and chronic respiratory diseases; which coincide directly with SDG target 3.4.1.
The Growing Burden of NCDs in Jordan and Around the World
Recent years have witnessed a dramatic shift from acute and infectious diseases to chronic diseases. By 2020, chronic diseases are projected to account for more than twice the number of deaths than from infectious diseases (50 million vs. 20 million). The problem is more acute in developing countries, where it is estimated that 7 out of 10 deaths in developing countries will be attributable to NCDs by 2020. In Jordan, NCDs accounted for 76% of disease-related deaths and cost the country $840 million in 2014.1
- Financial support to RHAS
- Infrastructure support (provision of medical equipment, office equipment and furniture to the selected HCCs
- Support for RHAS staff in the training and development of MoH medical personnel
- Printing of the awareness and educational material developed by RHAS for HCCs and the general public
- Number of direct beneficiaries (Sahab & Wadi Al Seer): 550 people
- Number of indirect beneficiaries (Sahab & Wadi Al Seer): 2750 people
- Number of educational sessions conducted: 1316 sessions
- Number of nutrition awareness sessions conducted: 346 sessions
Reductions in Disease Prevalence in Wadi Al Seer Clinic:
- 6.3% mean reduction in HbA1c for diabetic patients
- 2.3% mean reduction the diastolic blood pressure of hypertensive patients
- 2.8% mean reduction in the systolic blood pressure for hypertensive patients
- 1.18% mean reduction in BMI for participants in nutritional sessions
1“The burden of non communicable diseases in developing countries” Boutayeb, Abdesslam & Boutayeb, Saber. International Journal for Equity in Health 2005 4:2; DOI: 10.1186/1475-9276-4-
World Health Organization - Noncommunicable Diseases (NCD) Country Profiles , 2014, http://www.who.int/nmh/countries/jor_en.pdf